Management of cardiorenal syndrome Type I. A systematic review

Abstract

Introduction: Cardiorenal syndrome is a deregulation between the heart and kidneys that can lead to multi-organ system dysfunction if not adequately treated, which is why research into its management is justified. Objectives: Determine the management of Cardiorenal Syndrome Type I. Materials and methods: with the PRISMA 2020 statement, a review was carried out in databases such as Pubmed, Elsevier, Wiley with information from observational studies, randomized trials, meta-analysis, systematic reviews, documents of consensus or international guidelines, with the last date of searching for the resource April 9, 2024. Results: in patients with heart failure who received treatment with an intra-aortic pump (IAEP) with a catheter, it produced net fluid losses of 10.7 ± 6.5 L (P < 0.001) and significant reductions (P < 0.01) in central venous pressure. Patients on tidal peritoneal dialysis 90 days after discharge had fewer rehospitalizations for heart failure (14.3% vs. 32.5%, p = 0.022). The use of combined diuretics versus furosemide alone offers the same results in renal recovery, diuresis, vascular decongestion and adverse events, and may be considered a treatment. Conclusions: the results show that the main treatment is decongestion with diuretics, dialysis, using a drag pump with a vitally important role of ultrasound guidance during all stages of both cardiac and renal evaluation, helping in management